A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsPharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsBehavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders?Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Metabotropic glutamate receptor-mediated signaling in neurogliaStriatal glutamate release in L-DOPA-induced dyskinetic animalsPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingVU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyMetabotropic glutamate receptors: from the workbench to the bedside.Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans.Development of allosteric modulators of GPCRs for treatment of CNS disordersMolecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationLocal modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease.α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.Modeling Parkinson's disease in primates: The MPTP modelmGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortexp11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal functionα4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Mavoglurant as a treatment for Parkinson's disease.Molecular imaging of levodopa-induced dyskinesias.Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus biasmGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.New and emerging medical therapies in Parkinson's disease.mGlu5 negative allosteric modulators: a patent review (2013 - 2016).
P2860
Q21129423-E0306B3B-DCE9-4811-8EF4-55446C7ABCB0Q26852311-3FF22EE6-927F-4A59-BA4D-F215D20F6E3CQ27021464-C1CCDEC6-1FAB-4366-A1B7-320619694FC2Q27316872-ED4B2B7E-8315-450A-AF81-AF7A5F390EF9Q27323164-530FA1A0-6CD0-4F53-84DB-02871CAAE6BDQ27324174-9EAD9BA4-F48C-43A1-BAB8-CE9A5A86DEFAQ28385047-7F701714-6DFC-4BC8-BA59-E84B6E29FEC6Q28485942-7291F582-CF93-4733-98D4-93C32FA4A040Q28582674-F9E5E82B-FA46-4554-B4FC-B262B23FC70DQ30366876-96A15FC2-649A-46FC-A69F-74194B833237Q30448778-B822DD2B-7B7C-47B0-B26E-A3F3ED8D21ABQ33754643-9F23A17F-C615-4288-BCA2-8F8608608A6EQ34269340-C0CDAC0F-1E81-4D7E-B981-1F42D3245D7AQ34314041-80DD9052-4DD6-400D-9B04-2613A9F054B1Q34373958-33179C48-DDD8-4662-B5D5-F85F345DF900Q34468639-646AF6CE-8E81-4781-B3C3-C9B117E69CDEQ35000569-C51E5ABA-8CB7-42F1-A9D2-94C0271B5E8FQ35065682-38918571-9FCF-4B3D-B120-3A1C18FD58D7Q35124773-404A800B-752C-4050-8C63-E33B95A83A94Q35264378-1F21CAE3-CB55-4DCD-873F-2523B30D20B2Q35589979-03FAB273-9B27-4C57-B275-A48367A7FE04Q35738538-7C13D6B2-E09E-48C2-B8EF-2A65BE24A942Q35765748-A3F34124-D04E-4C5D-A912-CB1A8C904EA7Q35867117-08CA96B1-4BE7-4D4E-B6C6-05FF9157CE82Q36563103-1E085496-B660-4742-9561-27C8C3EB4D3AQ36936920-01855EA5-35E4-4760-8014-705DD7CB1EC8Q36936930-D3EAB75F-D86A-419D-A278-D6585B5B2448Q37506507-00CFA208-2328-4C80-B66B-BCB189CD6209Q37773480-26B1EFF7-8E0B-48D7-AF65-43FCEF09EAF6Q37924629-80AA27FF-A93A-4020-B9C1-7885E0A3F326Q38056852-86A2973B-EDBF-4D35-BF97-8BF82A1AEB06Q38190016-F333D123-691D-49A5-B2E6-F2FE015D050CQ38207680-466D6B0E-997F-4F48-91DE-5A39B5DCB9D5Q38222814-73F7F525-6E1B-4B99-A531-09007DCF1B7CQ38355582-69093BB5-A3EC-440B-94C8-2D0F350A2AD1Q38567309-905CAFF8-DB86-42B6-94FD-3EAFADEB8001Q38660240-6C7976D2-5133-481C-84AF-D99A44D56ED4Q38717833-A6DB356C-4162-4AE9-94DB-1FB0154C7EECQ38718194-01960F68-1B63-4A93-B529-563238770938Q39076410-27316EE6-D8F5-4F2C-82D4-0389E7B1B583
P2860
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@ast
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@en
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@nl
type
label
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@ast
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@en
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@nl
prefLabel
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@ast
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@en
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@nl
P2093
P1476
A mGluR5 antagonist under clin ...... parkinsonian rats and monkeys.
@en
P2093
Andrzej Dekundy
Hanna Iderberg
Jinlan Zhang
M Angela Cenci
Ren Baishen
Wojciech Danysz
P304
P356
10.1016/J.NBD.2010.05.001
P577
2010-05-07T00:00:00Z